Clinical Trial Update: A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Upadacitinib for Atopic Dermatitis–associated sleep disturbance has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis, Sleep Disturbance | Phase 3 | Status: WITHDRAWN